--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...
STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be ...
Hosted on MSN
Radiopharm Theranostics Accelerates RAD202 Clinical Trial Following Positive Safety Review
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Radiopharm Theranostics Limited Sponsored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback